GBT seeks to modernise traditional Chinese medicine for the benefit of all humanity
- The company plans to research, develop and manufacture high-quality skincare and nutraceutical products and distribute them around the world
With a mission to research, develop and manufacture high-quality skincare and nutraceutical products, Gallant BioTechnology (GBT) is placing Hong Kong front and centre in biotechnology innovation. Possessing multiple patents on the application of various biomaterials for health and wellness, the company is well-positioned to bring traditional Chinese medicine into worldwide distribution.
“I want Hongkongers to know that there are scientists in Hong Kong,” said molecular cloning expert Dr Gallant Chan, who is the CEO, founding director and principal scientist of GBT. “We can make our own products. There’s no need to just borrow other brands or just go do some trading. We can invent things. We can initiate something new – made in Hong Kong, designed in Hong Kong, invented in Hong Kong.”
GBT is establishing itself as the network node for Hong Kong’s biotech supply chain. It is beginning the journey in the nutraceuticals market with innovative products such as the Dr PIG skincare and Crowns OFF health drink collections. GBT adapted cutting-edge aerospace technology to develop an ultra-skin whitening formula using 147 small herbal molecules for its skincare collection. Meanwhile, Crowns OFF contains bioactive ingredients that fight Covid-19 along different pathways. More recently, the company launched the CANTICLES natural essential oils collection, an ethnomedicine of Uygur origin for treating cardiovascular problems and insomnia.
With a research laboratory in Zhongshan city, GBT is at the heart of the Guangdong-Hong Kong-Macau Greater Bay Area. The laboratory is the engine and a cornerstone of its biotech development through contract manufacturing alongside consultancy, testing and educational services. The company’s first stop will be Singapore, as a gateway to the entire Asia-Pacific, where it will pursue B2B collaborations and consignment schemes as part of long-term partnerships to grow global brands.
“The pharmacology is very clear and sharp at the molecular level, and we aim to unleash the beauty of scientific innovation to benefit all of humanity,” Chan said.
